Benralizumab is indicated for:
Irrespective of gender only Adults (18 years old or older)
Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Benralizumab is contraindicated in the following cases: